Have a feature idea you'd love to see implemented?
Let us know!
APLS Apellis Pharmaceuticals Inc
Price (delayed)
$31.9
Market cap
$3.97B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.02
Enterprise value
$4.04B
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims
Highlights
The gross profit has soared by 167% YoY and by 14% QoQ
APLS's revenue has soared by 162% year-on-year and by 14% since the previous quarter
The equity has declined by 10% since the previous quarter but it has increased by 2.1% year-on-year
The company's quick ratio fell by 10% QoQ but it rose by 6% YoY
Key stats
What are the main financial stats of APLS
Market
Valuations
Earnings
Shares outstanding
124.39M
Market cap
$3.97B
Enterprise value
$4.04B
Price to earnings (P/E)
N/A
Price to book (P/B)
16.38
Price to sales (P/S)
5.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.65
Revenue
$715.22M
Gross profit
$618.44M
Net income
-$250.1M
EBIT
-$211.54M
EBITDA
-$209.7M
Free cash flow
-$205.48M
Per share
Balance sheet
Liquidity
EPS
-$2.02
EPS diluted
-$2.02
Free cash flow per share
-$1.65
Book value per share
$1.95
Revenue per share
$5.76
TBVPS
$7.26
Total assets
$901.87M
Total liabilities
$664.75M
Debt
$470.45M
Equity
$237.12M
Working capital
$642.64M
Debt to equity
1.98
Current ratio
4.36
Quick ratio
3.54
Net debt/EBITDA
-0.34
Margins
Efficiency
Dividend
EBITDA margin
-29.3%
Gross margin
86.5%
Net margin
-35%
Operating margin
-31.2%
Return on assets
-29.2%
Return on equity
-103.9%
Return on invested capital
-36.3%
Return on capital employed
-29.8%
Return on sales
-29.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APLS stock price
How has the Apellis Pharmaceuticals stock price performed over time
Intraday
-2.39%
1 week
-3.94%
1 month
-5.98%
1 year
-46.71%
YTD
-46.71%
QTD
10.61%
Financial performance
How have Apellis Pharmaceuticals's revenue and profit performed over time
Revenue
$715.22M
Gross profit
$618.44M
Operating income
-$223.33M
Net income
-$250.1M
Gross margin
86.5%
Net margin
-35%
The gross profit has soared by 167% YoY and by 14% QoQ
APLS's revenue has soared by 162% year-on-year and by 14% since the previous quarter
APLS's operating margin has surged by 86% year-on-year and by 37% since the previous quarter
The company's net margin has surged by 84% YoY and by 34% QoQ
Growth
What is Apellis Pharmaceuticals's growth rate over time
Valuation
What is Apellis Pharmaceuticals stock price valuation
P/E
N/A
P/B
16.38
P/S
5.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.65
The EPS has surged by 62% year-on-year and by 26% since the previous quarter
The P/B is 35% less than the 5-year quarterly average of 25.1 and 31% less than the last 4 quarters average of 23.9
The equity has declined by 10% since the previous quarter but it has increased by 2.1% year-on-year
APLS's revenue has soared by 162% year-on-year and by 14% since the previous quarter
The stock's price to sales (P/S) is 98% less than its 5-year quarterly average of 240.9 and 50% less than its last 4 quarters average of 11.1
Efficiency
How efficient is Apellis Pharmaceuticals business performance
The return on sales has surged by 86% year-on-year and by 38% since the previous quarter
The company's return on invested capital has surged by 86% YoY and by 44% QoQ
APLS's ROA has soared by 58% year-on-year and by 27% since the previous quarter
APLS's ROE has soared by 50% YoY and by 25% QoQ
Dividends
What is APLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APLS.
Financial health
How did Apellis Pharmaceuticals financials performed over time
Apellis Pharmaceuticals's total assets is 36% more than its total liabilities
The company's current ratio fell by 14% QoQ
APLS's total liabilities is up by 13% year-on-year and by 3.8% since the previous quarter
The company's debt is 98% higher than its equity
The equity has declined by 10% since the previous quarter but it has increased by 2.1% year-on-year
The debt to equity has increased by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.